- Assessment of treatment effectiveness in patients with SVR 12.
| Treatment response | Overall N=140 | SOF-DCV with ribavirin (n=42) | SOF-DCV without ribavirin (n=98) | P-value |
|---|---|---|---|---|
| Intention to treat (ITT) analysis (n=140) | ||||
| Undetectable HCV RNA at EOT* | 130 (92.9) | 37 (88.1) | 93 (94.9) | 0.1520 |
| Detectable HCV RNA at EOT | 10 (7.1) | 5 (11.9) | 5 (5.1) | |
| SVR12 | 131 (93.6) | 38 (91.0) | 93 (94.9) | 0.666 |
| Failed | 9 (6.4) | 3 (7.2) | 6 (6.1) | |
| Per protocol (PP) analysis (n=136) | ||||
| Undetectable HCV RNA at EOT* | 129 (95.6) | 36 (94.7) | 93 (95.9) | 0.937 |
| Detectable HCV RNA at EOT | 5 (3.7) | 2 (5.3) | 3 (3.1) | |
| SVR12 | 131 (96.3) | 35 (92.1) | 96 (98.0) | 0.133 |
| Failed | 5 (3.7) | 3 (7.9) | 2 (2.0) | |
Values are presented as number and precentages (%).
EOT: end of treatment, SVR: sustained virologic response, HCV: hepatitis C virus, SOF-DCV: sofosbuvir-daclatasvir
↵* Two patients had no HCV RNA performed at EOT.